Immuron Ltd — Capital/Financing Update 2017

May 31, 2017

==> picture [567 x 98] intentionally omitted <==

==> picture [562 x 102] intentionally omitted <==

----- Start of picture text ----- ASX ANNOUNCEMENT: June 1, 2017----- End of picture text -----

==> picture [562 x 101] intentionally omitted <==

==> picture [562 x 101] intentionally omitted <==

==> picture [562 x 101] intentionally omitted <==

==> picture [562 x 101] intentionally omitted <==

----- Start of picture text ----- • Immruon’s major shareholder Grandlodge to provide another R&D refund acash advance loan as in previous years----- End of picture text -----

==> picture [562 x 102] intentionally omitted <==

----- Start of picture text ----- • Loan will ensure Immuron is funded through until after the release of theNASH Clinical Trial Interim Analysis results----- End of picture text -----

ABN: 80 063 114 045

Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735

==> picture [567 x 98] intentionally omitted <==

Immuron Secures R&D Cash Advance Loan Funding

Melbourne, Australia, June 1, 2017: Australian biopharmaceutical Company, Immuron Limited (ASX: IMC), is today pleased to announce that the Company has secured a AUD$1.5M loan in the form of a cash advance against its anticipated FY2017 R&D Tax Concession Refund from the Company’s major shareholder Grandlodge.

This cash advance loan will ensure the Company has sufficient funding through until after the release of the NASH clinical trial interim analysis results which will mark a milestone and inflection point for the Company which is to occur during early July 2017.

Immuron Chairman Dr Roger Aston commented;

“Following the Board’s decision this morning to put the interests of its shareholders at the forefront of any determination to progress with the NASDAQ listing at this time, it is a fantastic sign of solidarity to know that our major shareholder is willing to stand behind the Board’s decision and support the Company through the next period to reach our pending significant inflection point”

The specific details of the Grandlodge loan are confidential, but the loan terms of the loan are such that the loan is deemed to be armslength at commercially applicable market rates.

• • END - -

COMPANY CONTACT: IMMURON INVESTOR RELATIONS: Thomas Liquard Peter Taylor Chief Executive Officer NWR Communications Ph: +61 (0)3 9824 5254 Ph: +61 (0)4 1203 6231 thomasliquard@immuron.com peter@nwrcommunications.com.au

ABOUT IMMURON:

Immuron Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhea whilst its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: http://www.immuron.com

FORWARD-LOOKING STATEMENTS:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron

ABN: 80 063 114 045

Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735

==> picture [567 x 98] intentionally omitted <==

will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

ABN: 80 063 114 045

Suite 1, 1233 High Street, Armadale, Victoria AUSTRALIA 3143 www.immuron.com I Phone: + 61 (0)3 9824 5254 I Facsimile: + 61 (0)3 9822 7735